5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia
November 2020
in “
Journal of The European Academy of Dermatology and Venereology
”
TLDR 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
Several studies suggest that 5-alpha-reductase inhibitors (5ARIs), commonly used to treat androgenetic alopecia (male pattern baldness), may be associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. The studies found that males with androgenetic alopecia who were taking 5ARIs had a lower likelihood of experiencing COVID-19 symptoms compared to those who were not taking the medication. However, further research is needed to confirm these findings and to determine the mechanism behind this potential association.
